The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / COVID-19 & Pediatric Rheumatology

COVID-19 & Pediatric Rheumatology

September 14, 2021 • By Elizabeth Sloan, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
visivastudio / shutterstock.com

visivastudio / shutterstock.com

PRSYM 2021—Although primary COVID-19 infection has the most significant complications in adult patients, pediatric rheumatologists have also seen significant changes in their practice over the past year. With the emergence of COVID-19, the rise of a mysterious post-COVID hyper­inflammatory syndrome, now known as multisystem inflammatory syndrome in children (MIS-C), was identified, and pediatric rheumatologists have played a significant role in the recognition and management of this syndrome. In addition to the challenges of MIS-C, pediatric rheumatologists have also faced managing children with rheumatic disease during the pandemic.

You Might Also Like
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease
  • After COVID-19-Associated MIS-C, Immune Changes Resolve
Explore This Issue
September 2021

With these challenges in mind, Mark Gorelik, MD, and Dawn Wahezi, MD, MS, came together to discuss the pediatric rheumatology experience during COVID-19 on May 19 in a presentation titled Clinical Management of MIS-C and Rheumatic Disease During COVID.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clinical Management of MIS-C

Dr. Gorelik, an assistant professor in Pediatric Allergy, Immunology, and Rheumatology at Columbia University Irving Medical Center, New York, and New York-Presbyterian Morgan Stanley Children’s Hospital, opened the presentation with a discussion of MIS-C. He began with a disclaimer that all of us are still learning about MIS-C and there is still very little evidence to guide management of these patients. However, the ACR has published a document, Clinical Guidance for Pediatric Patients, to help clinicians care for MIS-C patients (https://www.rheumatology.org/Practice-Quality/Clinical-Support/COVID-19-Guidance#PediatricClinicalGuidance).

One of the greatest obstacles when discussing MIS-C is the lack of homogeneity in how the diagnosis is applied in the clinical setting. Dr. Gorelik pointed out that the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) definitions were designed to capture all cases, which may lead to over-treatment and incorrect diagnoses for some.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When reviewing published data, MIS-C definitions vary from center to center, further complicating the generalization of findings across institutions. This creates significant challenges when trying to recognize MIS-C in the clinical setting and when classifying patients for research.

In addition to varying definitions, optimal management of MIS-C has yet to be determined and differs greatly between institutions. It is currently unknown if every child should be treated with intravenous immunoglobulins (IVIG), high-dose vs. low-dose glucocorticoids and which, if any, biologics.

Dr. Gorelik highlighted two French studies, which independently demonstrated favorable outcomes in children with MIS-C who received steroids plus IVIG vs. those receiving IVIG alone.1,2 Dr. Gorelik then discussed his thought process when identifying, diagnosing and treating MIS-C, but he admitted that apart from the two French studies, this is currently an “evidence-free zone.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One striking feature of MIS-C is that it shares many characteristics with Kawasaki disease, one of the most common forms of vasculitis in children. While reviewing the similarities, Dr. Gorelik posed a question about MIS-C: Have we really never seen this before? He then reviewed literature about Kawasaki disease complicated by myocarditis and Kawasaki shock syndrome, highlighting the manifestations and treatments of these illnesses similar to MIS-C. Ultimately, he suggested that MIS-C may be one of several hyperinflammatory syndromes that includes Kawasaki disease and Kawasaki shock syndrome.

Finally, as we reach the one-year mark for many of the initial MIS-C patients, Dr. Gorelik shared that many patients have done very well after recovery from MIS-C, providing hope for good long-term outcomes.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), PRSYMIssue: September 2021

You Might Also Like:
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease
  • After COVID-19-Associated MIS-C, Immune Changes Resolve
  • ACR Releases COVID-19 & MIS-C Clinical Guidance for Kids with Rheumatic Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)